17 participants
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2020-07-23
- Start Date:
- 2016-06-06
- Completion:
- 2017-04-24
Conditions
- Basal Cell Nevus Syndrome
Interventions
- DRUG